Oct 13 (Reuters) - Oncogenex Pharmaceuticals Inc :
* Oncogenex announces results from the phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer
* Oncogenex Pharmaceuticals Inc - trial did not meet primary endpoint
* Oncogenex Pharmaceuticals -continuing to work with mts health partners who has been advising co in exploration of strategic alternatives since mid-August Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.